Eye infection breakthrough: new trial tests antivirals to save sight

NCT ID NCT03586284

Terminated Disease control Sponsor: University of California, San Francisco Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compared two antiviral medicines (oral valganciclovir and topical ganciclovir 2%) against a placebo for treating CMV-related inflammation in the front of the eye. The goal was to see which approach better controls the infection and reduces complications like pain, glaucoma, and vision loss. The trial enrolled 51 adults with confirmed CMV anterior uveitis and measured changes in viral load and eye inflammation over time.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CYTOMEGALOVIRUS ANTERIOR UVEITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

infectious anterior uveitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CYTOMEGALOVIRUS ANTERIOR UVEITIS

Contacts and locations

Show contact details

Locations

Chiang Mai University

Chiang Mai, Thailand
Chulalongkorn University

Bangkok, Thailand
Khon Kaen University

Khon Kaen, Thailand
Proctor Foundation, UCSF

San Francisco, California, 94158, United States